PPARA and cardiovascular disorder: In larger clinical studies, the dual PPARα/γ agonist aleglitazar (AleCardio and ALEPREVENT randomized clinical trials) showed no significant improvement of cardiovascular disease, but multiple significant side effects [89,90,91,92].